Development of a Clinical Prediction Rule for Venous Thromboembolism in Patients with Acute Leukemia

Al-Ani, Fatimah; Wang, Yimin Pearl; Lazo‐Langner, Alejandro

doi:10.1055/s-0039-3400303

Cited by 22 publications

(32 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In acute leukaemia, Al-Ani et al developed a simple predictive tool that may be used as standard of care but is awaiting ongoing external validation. 49 Despite the availability of different disease-specific scores in lymphoma-related thrombosis, in multiple myeloma, both SAVED and IMPEDED VTE scores performed better than currently used guidelines and can be used in risk stratification of patients with MM. 61,72 The guidelines already recommend the thromboprophylaxis of high-risk patients, given the significant reduction in mortality and morbidity.…”

Section: Conclusion and Practice Pointsmentioning

confidence: 97%

“…A misconception that thrombosis risk in patients with leukaemia was lower than that of solid tumours 48 is being replaced by recent studies which showed the incidence of thrombosis to be similar or even higher than in those with solid tumours. 49 The prevalence of thrombosis in acute myelocytic leukemia (AML) varies. In a cohort of 5394 cases, the largest cohort of AML, the 2-year cumulative incidence of deep vein thrombosis and/or pulmonary embolism was 5.2%.…”

Section: Acute Leukaemiamentioning

confidence: 99%

“…The score is statistically significant with a C-statistic of 0.664 (95% CI: 0.590-0.738) and ongoing external validation. 49…”

Section: Al-ani Et Al Risk Assessment Rulementioning

confidence: 99%

“…50 However, in a study by Al-Ani et al, the parameters were not predictive of thrombosis, but that study lacked D-dimer level sampling. 49 Table 6 present the parameters and their assigned scores for the ISTH DIC score.…”

Section: International Society On Thrombosis and Haemostasis Disseminated Intravascular Coagulation Score (Isth Dic)mentioning

confidence: 99%

See 3 more Smart Citations

Cancer-Associated Thrombosis: A Clinical Scoping Review of the Risk Assessment Models Across Solid Tumours and Haematological Malignancies

Mosaad¹,

Elnaem²,

Cheema³

et al. 2021

IJGM

View full text Add to dashboard Cite

Cancer-associated thrombosis (CAT) is a leading cause of death in cancer patients receiving outpatient chemotherapy. The latest guidelines emphasize stratifying the patients in terms of CAT risks periodically. Multiple risk assessment models (RAMs) were developed to classify patients and guide thromboprophylaxis to high-risk patients. This study aimed to discuss and highlight different RAMs across various malignancy types with their related advantages and disadvantages. A scoping review was conducted using predefined search terms in three scientific databases, including Google Scholar, Science Direct, and PubMed. The search for studies was restricted to original research articles that reported risk assessment models published in the last thirteen years (between 2008 and 2021) to cover the most recently published evidence following the development of the principal risk assessment score in 2008. Data charting of the relevant trials, scores, advantages, and disadvantages were done iteratively considering the malignancy type. Of the initially identified 1115 studies, 39 studies with over 67,680 patients were included in the review. In solid organ malignancy, nine risk assessment scores were generated. The first and most known Khorana risk score still offers the best available risk assessment model when used for high-risk populations with a threshold of 2 and above. However, KRS has a limitation of failure to stratify low-risk patients. The COMPASS-CAT score showed the best performance in the lung carcinoma patients who have a higher prevalence of thrombosis than other malignancy subtypes. In testicular germ cell tumours, Bezan et al RAM is a validated good discriminatory RAM for this malignancy subtype. CAT in haematological malignancy seems to be under-investigated and has multiple disease-related, and treatment-related confounding factors. AL-Ani et al score performed efficiently in acute leukemia. In multiple myeloma, both SAVED and IMPEDED VTE scores showed good performance. Despite the availability of different disease-specific scores in lymphoma-related thrombosis, the standard of care needs to be redefined.

show abstract

Section: Conclusion and Practice Pointsmentioning

confidence: 97%

Section: Acute Leukaemiamentioning

confidence: 99%

“…The score is statistically significant with a C-statistic of 0.664 (95% CI: 0.590-0.738) and ongoing external validation. 49…”

Section: Al-ani Et Al Risk Assessment Rulementioning

confidence: 99%

Section: International Society On Thrombosis and Haemostasis Disseminated Intravascular Coagulation Score (Isth Dic)mentioning

confidence: 99%

See 2 more Smart Citations

Cancer-Associated Thrombosis: A Clinical Scoping Review of the Risk Assessment Models Across Solid Tumours and Haematological Malignancies

Mosaad¹,

Elnaem²,

Cheema³

et al. 2021

IJGM

View full text Add to dashboard Cite

show abstract

“…It also opens ways to further important trials assessing thromboprophylaxis in high‐risk patients with other haematological malignancies. Specific VTE risk assessment models have already been developed for acute leukaemia (Al‐Ani risk score), myeloproliferative diseases (IPSET‐thrombosis), or lymphoma (ThroLy score) 10–12 . However, to date, only one randomised pilot trial assessing a DOAC for thrombosis prevention in adult patients with malignant haematologic conditions has been registered with http://ClinicalTrials.gov.…”

mentioning

confidence: 99%